Literature DB >> 26644815

Hepatic manifestations of non-steroidal inflammatory bowel disease therapy.

Robert Hirten1, Keith Sultan1, Ashby Thomas1, David E Bernstein1.   

Abstract

Inflammatory bowel disease (IBD) is composed of Crohn's disease and ulcerative colitis and is manifested by both bowel-related and extraintestinal manifestations. Recently the number of therapeutic options available to treat IBD has dramatically increased, with each new medication having its own mechanism of action and side effect profile. A complete understanding of the hepatotoxicity of these medications is important in order to distinguish these complications from the hepatic manifestations of IBD. This review seeks to evaluate the hepatobiliary complications of non-steroid based IBD medications and aide providers in the recognition and management of these side-effects.

Entities:  

Keywords:  Adverse drug reactions; Crohn’s disease; Drug induced liver injury; Hepatotoxicity; Inflammatory bowel disease; Ulcerative colitis

Year:  2015        PMID: 26644815      PMCID: PMC4663391          DOI: 10.4254/wjh.v7.i27.2716

Source DB:  PubMed          Journal:  World J Hepatol


  130 in total

1.  Infliximab as rescue therapy in paediatric autoimmune hepatitis.

Authors:  Jeremy Rajanayagam; Peter J Lewindon
Journal:  J Hepatol       Date:  2013-06-17       Impact factor: 25.083

2.  Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic.

Authors:  C M Nolan; S V Goldberg; S E Buskin
Journal:  JAMA       Date:  1999-03-17       Impact factor: 56.272

Review 3.  DRESS syndrome in a patient on sulfasalazine for rheumatoid arthritis.

Authors:  Fabrice Michel; Jean-Christophe Navellou; Denis Ferraud; Eric Toussirot; Daniel Wendling
Journal:  Joint Bone Spine       Date:  2005-01       Impact factor: 4.929

Review 4.  Sulfasalazine-induced hepatotoxicity in children with inflammatory bowel disease.

Authors:  D L Boyer; B U Li; J N Fyda; R A Friedman
Journal:  J Pediatr Gastroenterol Nutr       Date:  1989-05       Impact factor: 2.839

5.  Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis.

Authors:  Gert Van Assche; Geert D'Haens; Maja Noman; Séverine Vermeire; Martin Hiele; Katrien Asnong; Joris Arts; Andre D'Hoore; Freddy Penninckx; Paul Rutgeerts
Journal:  Gastroenterology       Date:  2003-10       Impact factor: 22.682

6.  Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide.

Authors:  J R Curtis; T Beukelman; A Onofrei; S Cassell; J D Greenberg; A Kavanaugh; G Reed; V Strand; J M Kremer
Journal:  Ann Rheum Dis       Date:  2010-01       Impact factor: 19.103

7.  Tuberculosis associated with blocking agents against tumor necrosis factor-alpha--California, 2002-2003.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2004-08-06       Impact factor: 17.586

8.  Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology.

Authors:  J M Kremer; G S Alarcón; R W Lightfoot; R F Willkens; D E Furst; H J Williams; P B Dent; M E Weinblatt
Journal:  Arthritis Rheum       Date:  1994-03

9.  Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up.

Authors:  K A Papp; C E M Griffiths; K Gordon; M Lebwohl; P O Szapary; Y Wasfi; D Chan; M-C Hsu; V Ho; P D Ghislain; B Strober; K Reich
Journal:  Br J Dermatol       Date:  2013-04       Impact factor: 9.302

10.  Clinically significant liver injury in patients treated with natalizumab.

Authors:  S Bezabeh; C M Flowers; C Kortepeter; M Avigan
Journal:  Aliment Pharmacol Ther       Date:  2010-02-16       Impact factor: 8.171

View more
  3 in total

Review 1.  Redox Control of Integrin-Mediated Hepatic Inflammation in Systemic Autoimmunity.

Authors:  Akshay Patel; Andras Perl
Journal:  Antioxid Redox Signal       Date:  2021-07-07       Impact factor: 7.468

2.  Identification and clinical significance of nodular regenerative hyperplasia in primary sclerosing cholangitis.

Authors:  Nazli Begum Ozturk; Maria Isabel Fiel; Thomas D Schiano
Journal:  JGH Open       Date:  2022-07-19

Review 3.  Liver-side of inflammatory bowel diseases: Hepatobiliary and drug-induced disorders.

Authors:  Stefano Mazza; Sara Soro; Maria Chiara Verga; Biagio Elvo; Francesca Ferretti; Fabrizio Cereatti; Andrea Drago; Roberto Grassia
Journal:  World J Hepatol       Date:  2021-12-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.